{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:20:00Z","timestamp":1788391200159,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.025","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"779-796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Oncology in Breast Cancer Surgery"],"prefix":"10.1016","volume":"40","author":[{"given":"Ali Benjamin","family":"Abbasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2026.05.025_bib1","unstructured":"Division of Cancer Prevention and Control CfDCaP. An Update on Cancer Deaths in the United States. Available at: https:\/\/www.cdc.gov\/cancer\/dcpc\/research\/update-on-cancer-deaths\/index.htm. Accessed December 1, 2023."},{"issue":"6871","key":"10.1016\/j.hoc.2026.05.025_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van \u2019t Veer","year":"2002","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.025_bib3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/jamaoncol.2017.1261","article-title":"Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades","volume":"3","author":"Esserman","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.025_bib4","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.025_bib5","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.025_bib6","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","article-title":"Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial","volume":"6","author":"Consortium","year":"2020","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2026.05.025_bib7","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","article-title":"Breast and ovarian cancer","volume":"348","author":"Wooster","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.025_bib8","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 4.2023 National Comprehensive Cancer Network2023 Available at: www.NCCN.org. Accessed December 1, 2023."},{"issue":"7418","key":"10.1016\/j.hoc.2026.05.025_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.025_bib10","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","article-title":"Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?","volume":"31","author":"Domchek","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.025_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jamaoncol.2015.28","article-title":"Multigene panel testing in oncology practice: how should we respond?","volume":"1","author":"Kurian","year":"2015","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.025_bib12","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1200\/JCO.2013.49.7388","article-title":"Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology","volume":"31","author":"Offit","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.025_bib13","unstructured":"NCCN Clinical Guidelines in Oncology (NCCN Guidelines) Breast Cancer Risk Reduction. Version 1.2023 2023. Available at: www.NCCN.org. Accessed December 1, 2023."},{"key":"10.1016\/j.hoc.2026.05.025_bib14","unstructured":"Available at: https:\/\/www.breastsurgeons.org\/docs\/statements\/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf. Accessed December 1, 2023."},{"issue":"6","key":"10.1016\/j.hoc.2026.05.025_bib15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.18.01631","article-title":"underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle?","volume":"37","author":"Beitsch","year":"2019","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.025_bib16","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1200\/JCO.19.02190","article-title":"Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer","volume":"38","author":"Yadav","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.025_bib17","unstructured":"Available at: https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/direct-consumer-tests. Accessed December 1, 2023."},{"issue":"4","key":"10.1016\/j.hoc.2026.05.025_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","article-title":"I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.hoc.2026.05.025_bib19","series-title":"Abstract CT136: evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: results from the I-SPY2 trial","author":"Schwab","year":"2019"},{"issue":"25","key":"10.1016\/j.hoc.2026.05.025_bib20","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.025_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.21037\/atm-21-7006","article-title":"Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study","volume":"10","author":"Cui","year":"2022","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.025_bib22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.025_bib23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2023.41.16_suppl.102","article-title":"Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS)","volume":"41","author":"Wolf","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.025_bib24","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1245\/s10434-023-13759-y","article-title":"Changes in surgical management of the axilla over 11 years - report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial","volume":"30","author":"Boughey","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.025_bib25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/bjs.10986","article-title":"Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer","volume":"105","author":"Tee","year":"2018","journal-title":"Br J Surg"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.025_bib26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.025_bib27","doi-asserted-by":"crossref","first-page":"e195410","DOI":"10.1001\/jamasurg.2019.5410","article-title":"Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the brightness randomized clinical trial","volume":"155","author":"Golshan","year":"2020","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.025_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.025_bib29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/SLA.0000000000005968","article-title":"Breast conservation surgery and mastectomy have similar locoregional recurrence following neoadjuvant chemotherapy: results from 1,462 patients on the prospective, randomized I-SPY2 trial","volume":"278","author":"Mukhtar","year":"2023","journal-title":"Ann Surg"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.025_bib30","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.025_bib31","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.025_bib32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.025_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.025_bib34","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.025_bib35","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2214\/ajr.184.6.01841774","article-title":"MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival","volume":"184","author":"Partridge","year":"2005","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.025_bib36","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1148\/radiol.2018180273","article-title":"Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial","volume":"289","author":"Partridge","year":"2018","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.025_bib37","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jso.25663","article-title":"MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer","volume":"120","author":"Sener","year":"2019","journal-title":"J Surg Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.025_bib38","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1080\/0284186X.2020.1797161","article-title":"The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response","volume":"59","author":"Mandish","year":"2020","journal-title":"Acta Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.025_bib39","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.19.02576","article-title":"Locoregional management after neoadjuvant chemotherapy","volume":"38","author":"Morrow","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.025_bib40","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","article-title":"Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial","volume":"23","author":"Kuerer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.025_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-023-06899-y","article-title":"De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study","volume":"199","author":"van Hemert","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.025_bib42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41523-021-00342-5","article-title":"A careful reassessment of anthracycline use in curable breast cancer","volume":"7","author":"Hurvitz","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"34","key":"10.1016\/j.hoc.2026.05.025_bib43","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2026.05.025_bib44","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.2016.71.4147","article-title":"Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 (NRG Oncology)","volume":"35","author":"Blum","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.025_bib45","series-title":"PreRCB in ISPY 2.0","author":"DeMichele","year":"2023"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.025_bib46","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.025_bib47","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S1470-2045(12)70209-7","article-title":"Circulating tumour cells in non-metastatic breast cancer: a prospective study","volume":"13","author":"Lucci","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.025_bib48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.025_bib49","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1245\/s10434-018-6540-4","article-title":"RNA-seq of circulating tumor cells in stage II-III breast cancer","volume":"25","author":"Lang","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.025_bib50","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1245\/s10434-021-11135-2","article-title":"Circulating tumor cell transcriptomics as biopsy surrogates in metastatic breast cancer","volume":"29","author":"Ring","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.025_bib51","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3390\/cancers14215238","article-title":"A multi-center clinical study to harvest and characterize circulating tumor cells from patients with metastatic breast cancer using the parsortix((R)) PC1 system","volume":"14","author":"Cohen","year":"2022","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.025_bib52","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.025_bib53","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1038\/ncomms9760","article-title":"Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer","volume":"6","author":"Murtaza","year":"2015","journal-title":"Nat Commun"},{"issue":"302","key":"10.1016\/j.hoc.2026.05.025_bib54","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"issue":"504","key":"10.1016\/j.hoc.2026.05.025_bib55","doi-asserted-by":"crossref","first-page":"eaax7392","DOI":"10.1126\/scitranslmed.aax7392","article-title":"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer","volume":"11","author":"McDonald","year":"2019","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.025_bib56","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","article-title":"Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer","volume":"26","author":"Parsons","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.025_bib57","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1200\/JCO.22.00908","article-title":"Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer","volume":"40","author":"Lipsyc-Sharf","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2026.05.025_bib58","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.05.025_bib59","doi-asserted-by":"crossref","first-page":"e2200148","DOI":"10.1200\/PO.22.00148","article-title":"Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse","volume":"6","author":"Cailleux","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.025_bib60","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.025_bib61","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2026.05.025_bib62","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.23.00638","article-title":"Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update","volume":"41","author":"Burstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.025_bib63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.025_bib64","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.025_bib65","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14737159.2019.1664290","article-title":"The current status of the clinical utility of liquid biopsies in cancer","volume":"19","author":"Snow","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"28","key":"10.1016\/j.hoc.2026.05.025_bib66","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.025_bib67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andre","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.hoc.2026.05.025_bib68","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.2022.40.16_suppl.1006","volume":"40","author":"Juric","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.025_bib69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.breast.2022.04.003","article-title":"Global guidelines for breast cancer screening: A systematic review","volume":"64","author":"Ren","year":"2022","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.025_bib70","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1016\/S1470-2045(13)70598-9","article-title":"Addressing overdiagnosis and overtreatment in cancer: a prescription for change","volume":"15","author":"Esserman","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.025_bib71","first-page":"1","article-title":"Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?","volume":"14","author":"Houssami","year":"2017","journal-title":"Cancer Biol Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.025_bib72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ng.3242","article-title":"Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer","volume":"47","author":"Michailidou","year":"2015","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.025_bib73","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng.2563","article-title":"Large-scale genotyping identifies 41 new loci associated with breast cancer risk","volume":"45","author":"Michailidou","year":"2013","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.025_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw290","article-title":"Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial","volume":"109","author":"Shieh","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2026.05.025_bib75","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-017-0035-5","article-title":"The WISDOM Study: breaking the deadlock in the breast cancer screening debate","volume":"3","author":"Esserman","year":"2017","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.025_bib76","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-148-5-200803040-00004","article-title":"Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model","volume":"148","author":"Tice","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2026.05.025_bib77","unstructured":"Available at: https:\/\/www.mypebs.eu\/the-project\/. Accessed December 1, 2023."},{"issue":"6499","key":"10.1016\/j.hoc.2026.05.025_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb9601","article-title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention","volume":"369","author":"Lennon","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.025_bib79","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.clbc.2023.06.004","article-title":"A review of AI-based radiomics and computational pathology approaches in triple-negative breast cancer: current applications and perspectives","volume":"23","author":"Corredor","year":"2023","journal-title":"Clin Breast Cancer"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.025_bib80","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.3390\/cancers13164104","article-title":"Blood-based multi-cancer detection using a novel variant calling assay (DEEPGEN(TM)): early clinical results","volume":"13","author":"Ris","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.025_bib81","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/genes12040507","article-title":"DEEPGEN(TM)-a novel variant calling assay for low frequency variants","volume":"12","author":"Hermann","year":"2021","journal-title":"Genes"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.025_bib82","doi-asserted-by":"crossref","first-page":"e222733","DOI":"10.1148\/radiol.222733","article-title":"Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study","volume":"307","author":"Arasu","year":"2023","journal-title":"Radiology"},{"issue":"41","key":"10.1016\/j.hoc.2026.05.025_bib83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jncimonographs\/lgq027","article-title":"Epidemiology of ductal carcinoma in situ","volume":"2010","author":"Kerlikowske","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.025_bib84","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS","volume":"103","author":"Wapnir","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.025_bib85","doi-asserted-by":"crossref","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","article-title":"The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)","volume":"9","author":"Hwang","year":"2019","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.025_bib86","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/2767-9764.CRC-22-0263","article-title":"Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort","volume":"2","author":"Glencer","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.025_bib87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41523-021-00267-z","article-title":"Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection","volume":"7","author":"Glencer","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.025_bib88","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.2009.1498","article-title":"Rethinking screening for breast cancer and prostate cancer","volume":"302","author":"Esserman","year":"2009","journal-title":"JAMA"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:02:36Z","timestamp":1788390156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0889858826000675"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.025","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Oncology in Breast Cancer Surgery","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}